These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36534022)

  • 21. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
    Bosiers M; Peeters P; Tessarek J; Deloose K; Strickler S;
    J Cardiovasc Surg (Torino); 2013 Feb; 54(1):115-22. PubMed ID: 23296421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
    Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
    Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amputation-free survival, limb symptom alleviation, and reintervention rates after open and endovascular revascularization of femoropopliteal lesions in patients with chronic limb-threatening ischemia.
    Perlander A; Jivegård L; Nordanstig J; Svensson M; Österberg K
    J Vasc Surg; 2020 Dec; 72(6):1987-1995. PubMed ID: 32276010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia.
    Kum S; Ipema J; Huizing E; Tan YK; Lim D; Lok IY; Hazenberg CE; Ünlü Ç
    Vasc Med; 2021 Jun; 26(3):267-272. PubMed ID: 33733963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
    Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
    Cipollari S; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    J Vasc Interv Radiol; 2018 Jan; 29(1):9-17.e1. PubMed ID: 29122449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
    Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
    Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
    Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
    J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
    Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
    Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
    J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the standard bolia technique versus subintimal recanalization plus Viabahn stent graft in the management of femoro-popliteal occlusions.
    Boufi M; Dona B; Orsini B; Auquier P; Hartung O; Alimi YS
    J Vasc Surg; 2010 Nov; 52(5):1211-7. PubMed ID: 20692789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting stents for the treatment of complex femoro-popliteal disease: a systematic review and meta-analysis.
    Katsogridakis E; Ballance L; Cawley O; Antoniou GA
    J Cardiovasc Surg (Torino); 2022 Jun; 63(3):299-307. PubMed ID: 30168308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
    Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
    J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
    [No Abstract]   [Full Text] [Related]  

  • 36. 24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent.
    Iida O; Fujihara M; Kawasaki D; Mori S; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA; Soga Y
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1367-1374. PubMed ID: 34235560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
    Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
    J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients.
    Brouillet J; Deloose K; Goueffic Y; Poirier M; Midy D; Caradu C; Ducasse E
    J Cardiovasc Surg (Torino); 2018 Jun; 59(3):392-404. PubMed ID: 27272981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of patency rates of self-expandable bare metal stents for endovascular treatment of femoro-popliteal arterial occlusive disease: Does stent design matter?
    Treitl KM; Woerner B; Schinner R; Czihal M; Notohamiprodjo S; Hoffmann U; Treitl M
    Eur Radiol; 2017 Sep; 27(9):3947-3955. PubMed ID: 28168366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.